These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17414513)

  • 21. Inflammation, infection, and prostate cancer.
    Klein EA; Silverman R
    Curr Opin Urol; 2008 May; 18(3):315-9. PubMed ID: 18382242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of prostate cancer. Part 1: chemoprevention.
    Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):419-25. PubMed ID: 16503858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrative analysis of genomic aberrations associated with prostate cancer progression.
    Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in Toll-like receptor genes--implications for prostate cancer development.
    Vidas Z
    Coll Antropol; 2010 Jun; 34(2):779-83. PubMed ID: 20698170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemopreventive efficacy of silymarin in skin and prostate cancer.
    Deep G; Agarwal R
    Integr Cancer Ther; 2007 Jun; 6(2):130-45. PubMed ID: 17548792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgens and prevention of prostate cancer.
    Sarvis JA; Thompson IM
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):271-7. PubMed ID: 18438176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation.
    Wang W; Bergh A; Damber JE
    Prostate; 2007 Aug; 67(11):1238-46. PubMed ID: 17570496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgens and the molecular epidemiology of prostate cancer.
    Chu LW; Reichardt JK; Hsing AW
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):261-70. PubMed ID: 18438175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
    Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
    Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic approaches to outcome prediction in prostate cancer.
    Febbo PG
    Cancer; 2009 Jul; 115(13 Suppl):3046-57. PubMed ID: 19544546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of recent evidence in support of a role for statins in the prevention of prostate cancer.
    Hamilton RJ; Freedland SJ
    Curr Opin Urol; 2008 May; 18(3):333-9. PubMed ID: 18382245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
    Kaarbø M; Klokk TI; Saatcioglu F
    Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation in prostate carcinogenesis.
    De Marzo AM; Platz EA; Sutcliffe S; Xu J; Grönberg H; Drake CG; Nakai Y; Isaacs WB; Nelson WG
    Nat Rev Cancer; 2007 Apr; 7(4):256-69. PubMed ID: 17384581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5alpha-reductase isozymes and androgen actions in the prostate.
    Zhu YS; Imperato-McGinley JL
    Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
    Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection, inflammation and prostate carcinogenesis.
    Omabe M; Ezeani M
    Infect Genet Evol; 2011 Aug; 11(6):1195-8. PubMed ID: 21397049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
    Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J
    Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
    Meiers I; Shanks JH; Bostwick DG
    Pathology; 2007 Jun; 39(3):299-304. PubMed ID: 17558856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.